Theranexus Logo

Theranexus

Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.

ALTHX | PA

Overview

Corporate Details

ISIN(s):
FR0013286259
LEI:
969500BFCV6IC7MFQP20
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON

Description

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-14 18:30
THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIA…
English 212.6 KB
2025-10-14 18:30
THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMME…
French 186.1 KB
2025-09-29 18:30
Theranexus devient THX Pharma : une évolution stratégique vers la commercialisa…
French 211.7 KB
2025-09-29 18:30
Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercializati…
English 209.9 KB
2025-05-13 18:00
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-W…
English 391.8 KB
2025-05-13 18:00
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE R…
French 352.9 KB
2025-04-29 19:05
URD 2024
French 10.6 MB
2025-04-29 19:00
THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT A…
English 336.5 KB
2025-04-29 19:00
THERANEXUS PUBLIE SES RÉSULTATS ANNUELS 2024, FAIT LE POINT SUR SES ACTIVITÉS E…
French 297.3 KB
2025-03-06 18:00
MODIFICATION DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
French 272.5 KB
2025-01-23 18:15
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
English 262.8 KB
2025-01-23 18:00
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
French 254.5 KB
2025-01-16 18:00
Information mensuelle relative au nombre total de droits de vote et d'actions c…
French 168.8 KB
2025-01-09 18:00
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
English 179.9 KB
2025-01-09 18:00
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
French 181.7 KB

Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Theranexus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Theranexus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.